Dublin, Aug. 07, 2018 (GLOBE NEWSWIRE) -- The "Nuclear Medicine/Radiopharmaceutical Global Market - Forecast To 2024" report has been added to ResearchAndMarkets.com's offering.

The nuclear medicine global market is estimated to reach $9,367.8 million by 2024 growing at mid single digit CAGR.

Increased radioisotopes applications, rise in public awareness, use of SPECT/CT and PET/CT imaging scans, abundance of radiopharmaceuticals, advancement in imaging technology (hybrid imaging) and alpha therapy based targeted cancer treatment is boosting nuclear medicine market growth. In addition, increasing need in emerging markets, production of radiopharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radio isotopes and replacement of old/traditional equipments are the opportunities likely to propel the growth of nuclear medicine market.

Nuclear medicinal market is classified based on modality into diagnosis-therapeutics. Diagnostics market held the largest market revenue in 2017 and is expected grow at single digit CAGR due to increase in SPECT and PET procedures. The therapeutics segment is expected to be the fastest growing segment at high double digit CAGR from 2017 to 2024 due to technological advancements in targeted treatment of cancers. Potential new radioisotopes in pipeline and advancement in neurological treatments are the key factors driving the growth of the therapeutics market. Diagnosis by products is segmented into SPECT and PET. SPECT market held the largest market due to increase in TC-99m isotope applications and product approvals. SPECT is segmented based on isotopes into Technetium (Tc-99m), Thallium (Tl-201), Gallium (Ga-67), Iodine (I-123), Samarium (Sm-153), Yttrium (Y-90), Rhenium (Re-186) and others. Technetium (Tc-99m) accounted for largest share in 2017 and is the fastest growing market with projected single digit CAGR growth during 2017 to 2024 due to increase in approvals of Tc-99m based cold kits for different applications. SPECT market by application is segmented into cardiology, pulmonary, oncology, nephrology, neurology, inflammation, thyroid gland, lymphology and others. Cardiology accounted for largest share in 2017 and remains fastest growing market due to increase in number of cardiac imaging cases using Tc-99m.

PET is the fastest growing segment at mid single digit CAGR from 2017 to 2024 due to increase in adoption of cyclotron for production of PET isotopes increasing its availability. The PET isotopes include Fluorodeoxyglucose (18F-FDG), Gallium (Ga-68), Rubidium (Rb-82) and others. The Fluorodeoxyglucose (18F-FDG) accounted for the largest share in 2017and remains the fastest growing market from 2017 to 2024 due to increase in application related to neurology, bone scan, infection and inflammation. PET by applications is segmented into cardiology, oncology, neurology, inflammation and others. Oncology accounted for largest share in 2017 and is the fastest growing market projected to grow with mid single CAGR from 2017 to 2024 due to increase in patient pool of lung cancer, thyroid cancer and breast cancer.

The nuclear medicine global market is a competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares and also acquiring small companies for product expansion.

Some of the key players of the nuclear medicine market are Curium Pharma (France), Bayer AG (Germany), GE Company (U.S.), Cardinal Health (U.S.), Jubilant Life science (India), Lantheus Medical Imaging (U.S.), Novartis International AG (Advanced accelerator) (Switzerland), South African Nuclear Energy Corporation (NTP Radioisotopes SOC Ltd) (South Africa), Siemens AG (Germany) and Fujifilm Holding Corporation (Japan).

Key Topics Covered:

1 Executive Summary

2 Introduction
2.1 Key Take Aways
2.2 Report Scope
2.3 Report Description
2.4 Markets Covered
2.5 Stakeholders
2.6 Research Methodology

3 Market Analysis
3.1 Introduction
3.2 Market Segmentation
3.3 Factors Influencing Market
3.3.1 Drivers And Opportunities Increased Applications Of Radiopharmaceuticals Rise In Public Awareness Usage Of Hybrid Imaging Technological Advancements Increasing Needs In Emerging Markets Production Of Radiopharmaceuticals From Cyclotrons Efficient Diagnosis And Treatments
3.3.2 Restraints And Threats Shorter Half-Life Of Radiopharmaceuticals High Cost And Supply Shortage Of Isotopes Radio Toxicity Shortage Of Qualified Technicians Regulatory Issues Threat From Traditional/Alternative Diagnostic Procedures Huge Capital Investment
3.4 Problem Areas
3.4.1 Closure Of Reactors
3.5 Winning Imperatives
3.5.1 Availability Of Technetium
3.6 Regulatory Guidelines
3.6.1 United States
3.6.2 Europe
3.6.3 Japan
3.6.4 India
3.6.5 China
3.6.6 South Korea
3.7 Reimbursement Scenario And Challenges
3.8 Clinical Trials
3.9 Patent Trends
3.10 Supply Chain Analysis
3.10.1 Reactors
3.10.2 Processing Facility
3.10.3 Generators Manufacturing Units
3.10.4 Hospitals And Central Radio Pharmacies
3.11 List Of Potential New Reactors
3.12 List Of Fda Aproved Radiopharmaceuticals
3.13 Porter's Five Force Analysis
3.13.1 Threat Of New Entrants
3.13.2 Threat Of Substitutes
3.13.3 Bargaining Power Of Suppliers
3.13.4 Bargaining Power Of Buyers
3.13.5 Competitive Rivalry
3.14 Market Share Analysis By Major Players
3.14.1 Nuclear Medicine Market
3.14.2 Spect Market
3.14.3 Pet Market
3.14.4 Tc-99 Market

4 Nuclear Medicine Global Market, By Modality
4.1 Introduction
4.2 Diagnostics
4.2.1 Radiopharmaceuticals For Diagnosis, By Isotopes Spect, By Isotopes Technetium (Tc-99M) Thallium (Tl-201) Gallium (Ga-67) Iodine (I-123) Samarium (Sm-153) Yttrium (Y-90) Rhenium (Re-186) Others Pet, By Isotopes Fluorodeoxyglucose (18F-Fdg) Gallium (Ga-68) Rubidium (Rb-82) Others
4.2.2 Nuclear Medicine For Diagnosis, By Application Spect By Application Cardiology Pulmonary Oncology Nephrology Neurology Inflammation Thyroid Glands Lymphology Others Pet By Application Oncology Neurology Cardiology Inflammation Others
4.3 Therapeutics
4.3.1 Nuclear Medicine For Therapeutics, By Radiation Type Beta Radiation Therapy Yttrium (Y-90) Iodine (I-131) Lutetium (Lu-177) Samarium (Sm-153) Rhenium (Re-186) Strontium (Sr-89) Erbium (Er-169) Others Alpha Radiation Therapy, By Isotopes Brachytherapy, By Isotopes Iodine (I-125) Cesium (Cs-131) Iridium (Ir-192) Palladium (Pd-103) Others
4.3.2 Nuclear Medicine Therapeutics, By Application Prostate Cancer Thyroid Cancer Liver Cancer Gep-Net Therapeutics Metastatic Bone Cancer Therapeutics Breast Cancer Therapeutics Other Therapeutic Applications

5 Nuclear Medicine Global Market, By End-Users
5.1 Introduction
5.2 Hospital
5.3 Ambulatory Centers
5.4 Diagnostic Centers
5.5 Other End-Users

6 Stable Isotopes
6.1 Introduction
6.2 Market Analysis
6.2.1 Factors Influencing Market
6.2.2 Drivers And Opportunities Increase In Research Activities (Pharmaceuticals And Biotechnology Sectors) Increasing Applications
6.2.3 Restraints And Threats High Cost Of Stable Isotopes Stable Isotopes-Side Effects And Safety Issues Stringent Regulations For Manufacturing And Use Of Stable Isotopes
6.3 Stable Isotopes Market, By Isotope
6.3.1 Carbon (C-13)
6.3.2 Deuterium (D2)
6.3.3 Oxygen (O-18)
6.3.4 Nitrogen (N-15)
6.3.5 Sulphur (S-32)
6.3.6 Others
6.4 Stable Isotopes Market, By Application
6.4.1 Introduction
6.4.2 Diagnostics And Therapy
6.4.3 Pharmaceuticals
6.4.4 Others
6.5 Stable Isotopes Market, By Geography
6.5.1 Introduction
6.5.2 North America
6.5.3 Europe
6.5.4 Asia-Pacific
6.5.5 Rest Of The World

7 Regional Analysis
7.1 Introduction
7.2 North America
7.2.1 U.S.
7.2.2 Others
7.3 Europe
7.3.1 Germany
7.3.2 France
7.3.3 Italy
7.3.4 Others
7.4 Asia-Pacific
7.4.1 Japan
7.4.2 China
7.4.3 Australia
7.4.4 Others
7.5 Rest Of The World
7.5.1 Brazil
7.5.2 Rest Of Latin America
7.5.3 Middle East And South Africa

8 Competitive Landscape
8.1 Introduction
8.2 Approvals And Agreements
8.3 Acquisition, Expansion And Collaboration
8.4 Others Developments

9 Major Player Profiles
9.1 Advance Accelerator Applications SA (Novartis)
9.2 Australian Nuclear Science And Technology Organization (ANSTO)
9.3 Bayer Group
9.4 Cardinal Health Inc.
9.5 Curium Pharma
9.6 Fujifilm Holdings Corporation
9.7 GE Company (GE Healthcare)
9.8 Jubilant Lifescience
9.9 Lantheus Medical Imaging Inc.
9.10 Sotera Health Llc (Nordion Inc)
9.11 South African Nuclear Energy Corporation (NECSA) (NTP Radioisotopes Soc Ltd)
9.12 Siemens AG

Companies Mentioned

  • 13 C Molecular
  • Actinium Pharmaceuticals, Inc
  • Advanced Nuclear Medicine Ingredients
  • Alpha Tau Medical
  • Arronax Cyclotron
  • Australian Nuclear Science and Technology Organization (ANSTO)
  • Bayer Group
  • Becton, Dickinson and Company (Bard Medicals)
  • Beijing Zhibo Biomedical Technology Co. Ltd
  • Best Medical International, Inc
  • Blue Earth Diagnostics Limited
  • Board of Radiation & Isotope Technology
  • Bracco Group
  • BTG International Ltd
  • BV Cyclotron VU
  • Cardinal Health Inc.
  • Cellectar Biosciences
  • Center of Molecular Research
  • Centre for Probe Development and Commercialization
  • China National Nuclear Corporation (China Isotope & Radiation Corporation)
  • Clarity's Pharmaceuticals
  • Curium Pharma
  • Eckert & Ziegler Strahlen
  • Eczacibasi-Monrol Nuclear Products
  • Eli Lilly & Co (Avid Radiopharmaceuticals)
  • Eurisotop
  • Fujifilm Corporation
  • GE Company
  • Huayi Technology Co., Ltd (Huayi Isotopes Co)
  • Institute of Isotopes
  • International Isotopes Inc.
  • Iso-Analytical Ltd.
  • IsoAid LLC
  • Isoflex Isotope
  • Isorad Ltd
  • Isoray Medical Inc
  • IsoSciences, LLC
  • Isotopia Molecular Imaging Ltd.
  • iThemba labs
  • ITM Isotopen Technologien Mnchen AG
  • Jubilant Lifescience (Triad Isotopes & Draximage)
  • Lantheus Medical Imaging Inc
  • Linde Group
  • Los Alamos National Laboratory (LANL)
  • Medical Isotopes Inc
  • Merck KGaA (Sigma Aldrich-Isotec Inc)
  • Mitsubishi Chemical Holdings (Tayyo Nippon Sanso Corporation)
  • Navidea Biopharmaceuticals Inc
  • Nihon Medi Physics Co Ltd
  • Novartis International AG (Advanced accelerator Application (AAA) )
  • Nuclear Research and Consultancy Group (NRG)
  • Omicron Biochemicals Inc.
  • Orano Med (Areva Med)
  • Otsuka Pharmaceutical (Cambridge Isotope Laboratories, Inc.)
  • Pars Isotope
  • Perkin Elmer
  • Perma-Fix Environmental Services, Inc. (Perma Fix Medical SA) (Poland)
  • Perma-Fix Medical SA
  • ROTOP Pharmaka GmbH
  • Shangai GMS Pharma
  • Shangai Research Institute of Chemical Industry
  • Shine Medical Technologies, Inc
  • Siemens AG
  • Sofie Biosciences Inc (Zevacor Pharma)
  • Solcom Limited
  • Sotera health, LLC (Nordion Inc)
  • South African Nuclear Energy Corporation (NTP Radioisotopes SOC Ltd)
  • Swan Isotopen AG
  • Teva Pharmaceutical Industries Ltd (Auspex Pharmaceuticals)
  • Theragenics Corporation
  • Theragnostics Ltd
  • Tianjin Seeds Biological Pharmacy Co. Ltd
  • Yantai DongCheng Biochemicals Co. Ltd.

For more information about this report visit https://www.researchandmarkets.com/research/gvktj5/9_36_bn_nuclear?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Nuclear Medicine and Radiopharmacology